{
    "clinical_study": {
        "@rank": "68622", 
        "acronym": "DEB-SFA-LONG", 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to assess safety and efficacy of the Drug Eluting\n      Balloon (DEB) technology for the treatment of the Superficial Femoral Artery (SFA) ischemic\n      obstructive  vascular disease in patients presenting with long lesions. As secondary aim\n      this study is going to explore treatment effect on a number of procedural and clinical\n      endpoints in order to collect information to design a future comparative effectiveness\n      study."
        }, 
        "brief_title": "Drug Eluting Balloon (DEB) and Long Lesions of Superficial Femoral Artery (SFA) Ischemic Vascular Disease", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Vascular Diseases", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is aimed at collecting preliminary safety and efficacy data related to the use of\n      Drug Eluting Balloon (DEB) technology for the treatment of symptomatic Superficial Femoral\n      Artery (SFA) ischemic vascular disease in patients presenting with long lesions.\n\n      The present clinical evaluation is intended as a prospective observational data collection\n      of patient treatment in full accordance with institution standard practice and utilizing an\n      approved (CE marked) DEB currently available on the market."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented ischemic, symptomatic arterial disease in the femoral-popliteal arteries\n             according to Rutherford Category 2, 3 or 4;\n\n          -  Target lesion consists of a single solitary or multiple adjacent de novo or\n             restenotic lesions (non-in-stent) with diameter stenosis \u2265 70%  by visual estimate\n             and cumulative lesion length \u2265 15 cm;\n\n          -  Target vessel is the superficial femoral artery and/or proximal popliteal  artery\n             (above the knee);\n\n          -  Life expectancy >1 year in the Investigator's opinion;\n\n          -  Written informed consent.\n\n        Exclusion criteria:\n\n        Given the observational nature of the study, no study-specific but only clinical exclusion\n        criteria will apply:\n\n          -  Patient unwilling or unlikely to comply  with FU schedule;\n\n          -  Administration of local or systemic thrombolytic therapy within 48 hours prior to the\n             index procedure;\n\n          -  Known allergies or sensitivities to heparin, aspirin, other\n             anticoagulant/antiplatelet therapies, and/or paclitaxel;\n\n          -  Additional planned cardiac or peripheral percutaneous or surgical intervention\n             including CABG within 30 days following the study procedure;\n\n               -  15 cm long inflow lesion (\u226550% DS) or occlusion (any length) in the ipsilateral\n                  Iliac artery;\n\n          -  Failure to successfully treat < 15 cm long inflow lesion in the ipsilateral Iliac\n             artery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients affected by lower extremities artery disease (LEAD) and referred to the\n        participating centres for the endovascular treatment of de novo or restenotic lesions (no\n        in stent restenosis) in the superficial femoral and proximal popliteal arteries will be\n        considered for the study"
            }
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658540", 
            "org_study_id": "ESREFO09"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug Eluting Balloon (DEB) technology", 
            "long SFA lesions disease"
        ], 
        "lastchanged_date": "May 18, 2014", 
        "location": [
            {
                "contact": {
                    "email": "gschiavina@esrefo.org", 
                    "last_name": "Giulia Schiavina"
                }, 
                "facility": {
                    "address": {
                        "city": "Cotignola", 
                        "country": "Italy", 
                        "state": "Ravenna", 
                        "zip": "48010"
                    }, 
                    "name": "Maria Cecilia Hospital"
                }, 
                "investigator": {
                    "last_name": "Chiara Grattoni, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy", 
                        "zip": "70124"
                    }, 
                    "name": "Anthea Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "bspagnolo@esrefo.org", 
                    "last_name": "Barbara Spagnolo, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lecce", 
                        "country": "Italy", 
                        "zip": "73100"
                    }, 
                    "name": "Citt\u00e0 di Lecce Hospital"
                }, 
                "investigator": {
                    "last_name": "Armando Liso, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Mriina@esrefo.org", 
                    "last_name": "Marco Riina"
                }, 
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "zip": "90141"
                    }, 
                    "name": "Maria Eleonora Hospital, GVM Care & Research"
                }, 
                "investigator": [
                    {
                        "last_name": "Giuseppe Vadal\u00e0, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Antonio Micari, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rapallo", 
                        "country": "Italy"
                    }, 
                    "name": "ICLAS Rapallo"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "azeoli@esrefo.org", 
                    "last_name": "Annarita Zeoli"
                }, 
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy"
                    }, 
                    "name": "Maria Pia Hospital"
                }, 
                "investigator": {
                    "last_name": "Elvis Brscic, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Safety and Efficacy of the Drug Eluting Balloon (DEB) for the Treatment of the Superficial Femoral Artery (SFA) Ischemic Vascular Disease in Symptomatic Patients Presenting With Long Lesions: a Pilot Study", 
        "other_outcome": [
            {
                "description": "the rate of instrumental restenosis as determined by duplex ultrasound Peak Systolic Velocity Ratio (PSVR) \u2264 2.4 post-index procedure  and the rate of instrumental restenosis as determined by duplex ultrasound Peak Systolic Velocity Ratio (PSVR) \u22642 and \u22643.5 at 12 months (6, and 24 if available) or at unscheduled visit, as evaluated by an independent core lab", 
                "measure": "rate of instrumental restenosis", 
                "safety_issue": "No", 
                "time_frame": "within the first 24 months after percutaneous treatment"
            }, 
            {
                "description": "rate of procedural success i.e. complete revascularization in the absence of peri-procedural complications", 
                "measure": "procedural success rate", 
                "safety_issue": "No", 
                "time_frame": "at the end of percutaneous treatment"
            }, 
            {
                "description": "walking capacity as assessed by walking impairment questionnaire (WIQ) and quality of life (EQ5D questionnaire) at 6, 12 and 24 months post-procedure vs. baseline", 
                "measure": "walking capacity and quality of life", 
                "safety_issue": "No", 
                "time_frame": "whithin 6, 12 and 24 months post-procedure vs. baseline"
            }
        ], 
        "overall_contact": {
            "email": "mcjori@esrefo.org", 
            "last_name": "Maria Cristina Jori, MD", 
            "phone": "0039 0545217031"
        }, 
        "overall_contact_backup": {
            "email": "bspagnolo@esrefo.org", 
            "last_name": "Barbara Spagnolo, PhD", 
            "phone": "0039 0832229426"
        }, 
        "overall_official": {
            "affiliation": "Maria Eleonora Hospital, GVM Care & Research", 
            "last_name": "Antonio Micari, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary patency is defined as freedom from the combined endpoints of clinically-driven target lesion revascularization (TLR) and >50% restenosis in the treated lesion. Clinically driven TLR is defined as any re-intervention within the target lesion due to symptoms or drop of ABI of \u226520% or >0.15 when compared to post-procedure. Restenosis > 50% is defined by a peak systolic velocity ratio (PSVR) > 2.4.", 
            "measure": "rate of primary patency", 
            "safety_issue": "No", 
            "time_frame": "within the first 12 months after percutaneous treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "evaluate the incidence of the composite of all Major Adverse Events (MAE) through 24 months i.e. the first occurrence of any of the following: death from any cause, major target limb amputation, thrombosis at the target lesion site", 
                "measure": "composite of all Major Adverse Events (MAE)", 
                "safety_issue": "Yes", 
                "time_frame": "within the first 24 months after percutaneous treatment"
            }, 
            {
                "description": "to assess the incidence of Major Adverse Cardiac and Cerebrovascular event (MACCE) individual components through 24 months", 
                "measure": "incidence of Major Adverse Cardiac and Cerebrovascular event (MACCE)", 
                "safety_issue": "No", 
                "time_frame": "within the first 24 months after percutaneous treatment"
            }, 
            {
                "description": "compare clinical improvement as assessed by Rutherford Class changes at 6, 12 and 24 months with respect to baseline", 
                "measure": "clinical improvement as assessed by Rutherford Class changes", 
                "safety_issue": "No", 
                "time_frame": "within 6, 12 and 24 months vs baseline"
            }
        ], 
        "source": "Ettore Sansavini Health Science Foundation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ettore Sansavini Health Science Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}